Customize
Quick Links
Past Events
2017

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Pfizer.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

Medical Crossfire®: Integrating CDK4/6 Inhibitors into the Management of Breast Cancers

Medical Crossfire®: Integrating CDK4/6 Inhibitors into the Management of Breast Cancers


Saturday, March 12, 2016
7:00 AM – 8:30 AM
Fontainebleau Miami Beach (Fontaine/ Fleur de Lis)

Overview

"Medical Crossfire®: Integrating CDK4/6 Inhibitors into the Management of Breast Cancers" is a live continuing medical education (CME)-certified symposium to be held adjunct to the 33rd Annual Miami Breast Cancer Conference®.

Treatment of estrogen receptor–positive (ER+), human epidermal growth factor 2–negative (HER2-), metastatic breast cancer remains an area of significant unmet clinical need. Efforts to improve upon the outcomes achieved with initial endocrine therapy have been largely unsuccessful, but active research into this area is expanding the arsenal of targeted therapies available for metastatic breast cancer. While novel therapies and combinations—such as a recently FDA-approved oral, highly selective CDK4/6 inhibitor—undeniably benefit patients with breast cancer, they also add markedly to the complexity of the treatment decision-making process. With the potential for broader indications of CDK4/6 inhibitory therapy in breast and other tumor types, these agents are likely to become more routinely used.

For this not-to-be-missed symposium, we are bringing together a panel of internationally recognized experts in breast cancer therapy to discuss how CDK4/6 inhibitors can advance the care of these patients, today and in the future. Faculty will cover key topics in the treatment of ER+, HER2-, metastatic breast cancer including:

  • Current perspectives on the management of these patients and unmet clinical needs
  • Overview of the CDKs in the cell cycle and as novel targets for drug development in breast cancer
  • Strategies for incorporating emerging efficacy and safety data from clinical trials of CDK4/6 inhibitory therapies into individualized treatment planning
    • Recognition and management of CDK inhibitor–related toxicities
    • Patient criteria that may change the course of treatment or treatment selection
    • Where does consensus exist, and where are more data needed?
  • Expansion of therapeutic CDK4/6 inhibition toward new indications, novel combinations, and additional breast tumor types

The symposium will be held at the Fontainebleau Miami Beach on March 12 from 7:00 am–8:30 am. Please join us live in Miami to learn the latest and greatest state-of-the-art science around CDK4/6 inhibitory therapies in ER+, HER-, metastatic breast cancer, as well as the most up-to-date information on appropriate and optimal use of these agents.

This will be the only independent CME-certified symposium focused entirely on CDK4/6 inhibitory therapy for metastatic breast cancer. You won’t want to miss this program!

Target Audience

This activity is intended for all attendees of the Miami Breast Cancer Conference® including medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer may also participate.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Explain the mechanism of action of CDK 4/6 inhibition in the treatment of metastatic breast cancer
  • Discuss the role of emerging CDK4/6 inhibitory therapies in the treatment of metastatic breast cancer
  • Evaluate new and emerging clinical trial data that may change standards of care for patients with metastatic breast cancer
  • Identify strategies for the mitigation and management of predictable adverse events associated with emerging CDK4/6 inhibitory therapies in the management of metastatic breast cancer

Co-Chairs

Debu Tripathy, MD
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
 

Joyce O'Shaughnessy, MD
Chair, Breast Cancer Research
Celebrating Women Chair in Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
The US Oncology Network
Dallas, TX


 







Become a Member

Forgot Password?
Filter By